OK TO ENTER: /RC/

AMENDMENTS TO THE CLAIMS

1. (currently amended) A testosterone oral dosage formulation for administration to a subject comprising:

a substantially solid polyethylene glycol carrier which comprises from about 30% w/w to about 80% w/w of the formulation, having a molecular weight range of from about 100 to about 20,000 or a mixture thereof;

and a therapeutically effective amount of testosterone, or is its pharmaceutically acceptable salts or esters, or a mixture thereof in the carrier ranging from about 2.5 mg to about 45 mg, said formulation providing a therapeutically effective testosterone serum level ranging from about 15 ng/dl to about 1200 ng/dl when administered to the subject.

- 2. (original) The formulation of claim 1, wherein the amount of testosterone in the carrier is from about 5 mg to about 15 mg.
- 3. (original) The formulation of claim 2, wherein the amount of testosterone is about 10 mg.
- 4. (original) The formulation of claim 1, wherein the polyethylene glycol of said carrier has an average molecular weight of from about 400 to about 15,000.
- 5. (original) The formulation of claim 4, wherein the polyethylene glycol of said carrier has an average molecular weight of from about 1,000 to about 10,000.
- 6. (original) The formulation of claim 1, wherein the carrier comprises from about 50% w/w to about 80% w/w of the formulation.
- 7. (original) The formulation of claim 6, wherein the carrier comprises from about 60% w/w to about 80% w/w of the formulation.

- 8. (original) The formulation of claim 7, wherein the carrier comprises about 70% w/w of the formulation.
- 10. (original) A testosterone oral dosage formulation for administration to a subject, comprising: a substantially solid polyethylene glycol carrier having a molecular weight of from about 1,000 to about 10,000, said carrier comprising at least about 70% w/w of the formulation; and from about 10 mg to about 15 mg of testosterone in the carrier.
- 11. (withdrawn) A method of administering testosterone to a subject, comprising: providing a testosterone formulation as recited in any one of claims 1-10; and orally administering the formulation to the subject.
- 12. (withdrawn) The method of claim 11, wherein the subject is a male.
- 13. (withdrawn) The method of claim 11, wherein the subject is a female.
- 14. (withdrawn) A method of treating or ameliorating a condition in a subject for which testosterone is effective comprising: providing a testosterone formulation as recited in any one of claims 1-10; and orally administering the formulation to the subject in a therapeutically effective regimen.
- 15. (withdrawn) A method of making an oral dosage testosterone formulation, comprising: forming a dispersion of testosterone in a molten polyethylene glycol carrier; cooling the dispersion into a substantially solid mass; and dividing the mass into portions suitable for administration of a single testosterone dose.
- 16. (withdrawn) The method of claim 15, further comprising extruding the molten polyethylene glycol carrier during the step of cooling to form an extrusion product.

- 17. (withdrawn) The method of claim 16, further comprising cutting the extrusion product into caplets.
- 18. (withdrawn) The method of claim 15, wherein the step of dividing further comprises reducing the solid mass to flakes, granules, or powder and separating the flakes granules, or powder into a single dosage amount.
- 19. (withdrawn) The method of claim 18, further comprising molding the single dosage unit into a solid state form.
- 20. (withdrawn) The method of claim 19, wherein the step of molding is accomplished by injection molding.
- 21. (withdrawn) The method of claim 19, wherein the step of molding is accomplished by pressing.
- 22. (withdrawn) The method of claim 19, wherein the solid state form is a tablet.
- 23. (withdrawn) The method of claim 18, further comprising encapsulating the single dosage amount with a capsule.
- 24. (withdrawn) The method of claim 15, wherein the testosterone is uniformly dispersed in the molten polyethylene glycol carrier.
- 25. (currently amended) A testosterone oral dosage formulation for administration to a subject comprising:
- a) a substantially solid polyethylene glycol carrier present in the formulation from about 30% w/w to about 80% w/w, comprising:
 - i) a first polyethylene glycol having a molecular weight range of from about 100 to about 20,000;

- ii) a second polyethylene glycol having a molecular weight range of from about 100 to about 20,000;
- iii) third polyethylene glycol having a molecular weight range of from about 100 to about 20,000;
- b) a therapeutically effective amount of testosterone, or is its pharmaceutically acceptable salts or esters, or a mixture thereof in the carrier ranging from about 2.5 mg to about 45 mg, wherein said first, second, and third polyethylene glycols having differing molecular weights and said formulation provides a therapeutically effective testosterone serum level ranging from about 15 ng/dl to about 1200 ng/dl when administered to the subject.
- 26. (previously presented) The formulation of claim 25, wherein the first polyethylene glycol has a molecular weight range of from about 100 to about 1600.
- 27. (previously presented) The formulation of claim 25, wherein the second polyethylene glycol has a molecular weight range of from about 1600 to about 5000.
- 28. (previously presented) The formulation of claim 25, wherein the third polyethylene glycol has a molecular weight range of from about 5000 to about 20,000.
- 29. (previously presented) The formulation of claim 25, wherein the formulation comprises a fourth polyethylene glycol, having a weight range of from about 100 to about 20,000 such that the fourth polyethylene glycol has a different molecular weight than the first, second, and third polyethylene glycols.
- 30. (currently amended) The formulation of claim 29, wherein the formulation comprises a fifth polyethylene glycol, having a weight range of from about 100 to about 20,000 such that the <u>fourth</u> <u>fifth</u> polyethylene glycol has a different molecular weight than the first, second, <u>and</u> third, <u>and</u> <u>fourth</u> polyethylene glycols.
- 31. (previously presented) The formulation of claim 25, wherein the amount of testosterone in the

carrier is from about 5 mg to about 15 mg.

- 32. (previously presented) The formulation of claim 31, wherein the amount of testosterone in about 10 mg.
- 33. (previously presented) The formulation of claim 25, wherein the carrier comprises from about 50% w/w to about 80% w/w of the formulation.
- 34. (previously presented) The formulation of claim 25, wherein the carrier comprises from about 60% w/w to about 80% w/w of the formulation.
- 35. (previously presented) The formulation of claim 25, wherein the carrier comprises about 70% of the formulation.
- 36. (currently amended) A testosterone oral dosage formulation for administration to a subject comprising:
- a) a substantially solid polyethylene glycol carrier present in the formulation at least about 70% w/w comprising:
 - i) a first polyethylene glycol having a molecular weight range of from about 100 to about 1,600;
 - ii) a second polyethylene glycol having a molecular weight range of from about 1,600 to about 5,000;
 - iii) third polyethylene glycol having a molecular weight range of from about 5,000 to about 20,000;
- b) a therapeutically effective amount of testosterone, or is its pharmaceutically acceptable salts or esters, or a mixture thereof in the carrier ranging from about 10 mg to about 15 mg, wherein said first, second, and third polyethylene glycols having differing molecular weights and said formulation provides a therapeutically effective testosterone serum level ranging from about 15 ng/dl to about 1200 ng/dl when administered to the subject.